The prototype device (for administering remote ischemic preconditioning-RIPC) has gone through a rigorous R&D in the past few years such that the design, performance, accuracy and reliability of the device has evolved through 3 generations. From Gen 1 to 2, main improvement was to deliver a patient-specific dosage of ischemic conditioning. The cost for this improvement was paid partially by the previous IP fund. From Gen 2 to 3 as evident from the images below, device reformed to a commercially viable and more competitive appearance with significant improvements toward CE and TGA regulatory standards. To cover the costs for R&D of generation 3, our team heavily relies on a new IP development fund to accomplish this milestone.
|Short title||RIPC 3|
|Effective start/end date||1/12/17 → 1/12/18|